The biopharmaceutical company reported earnings of $3.22 per share, up from $1.84 for the year ago period.
Revenue increased year over year, to $8.3 billion from $6.0 billion in the 2014 third quarter.
Gilead had been forecast to report earnings of $2.87 per share on revenue of $7.82 billion by analysts surveyed by Thomson Reuters.
The company increased its 2015 full-year net product sales guidance to a range between $30,000 and $31,000 from a prior range between $29,000 and $30,000.
Separately, TheStreet Ratings team rates GILEAD SCIENCES INC as a Buy with a ratings score of A-. TheStreet Ratings Team has this to say about their recommendation:
We rate GILEAD SCIENCES INC (GILD) a BUY. This is based on the convergence of positive investment measures, which should help this stock outperform the majority of stocks that we rate. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, attractive valuation levels and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.
You can view the full analysis from the report here: GILD